Skip to main content

Table 1 Patient *1 characteristics assessed based on smoking status and TP53-mutations

From: Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma

  Total Smokers*2 Non-smokers*2 p-value MutantTP53 Wild-typeTP53 p-value
(N = 161: 69%) (N = 71: 31%)   (N = 147: 63%)
(N = 87: 37%)
Smoking status – PYs        
25%/50%/75% 0/25/40 25/40/46 0/0/0 <0.0001*3 8/30/40 0/20/40 0.085*3
Smokers – no. (%) 161 (69) - - - 108 (74) 53 (61) 0.030*4
TP53-mutations – no. (%) 147 (63) 108 (67)*7 37 (52) *7 0.030*4    
Age, years – yr. mean ± s.d. 63.2 ± 10.9 63.5 ± 10.2 62.6 ± 12.6 0.56*5 64.1 ± 10.4 61.6 ± 11.5 0.082*5
Men – no. (%)*6 187 (80) 152 (94) 33 (46) <0.001*4 122 (83) 65 (75) 0.13*4
Drinking status – no. (%)*6     <0.001*4    0.043*4
Non-drinker 89 (38) 35 (22) 53 (75)   50 (34) 39 (45)  
Moderate drinker 74 (32) 64 (40) 9 (13)   55 (37) 19 (22)  
Heavy drinker 71 (30) 62 (39) 9 (13)   42 (29) 29 (33)  
Primary site of tumor – no. (%)*6     0.030*4    0.13*4
Oropharyngea 63 (27) 47 (29) 16 (23)   37 (25) 26 (30)  
Hypopharyngeal 64 (27) 47 (29) 16 (23)   49 (33) 15 (17)  
Laryngeal 29 (12) 24 (15) 5 (7)   17 (12) 12 (14)  
Oral 57 (24) 32 (20) 25 (35)   32 (22) 25 (29)  
Nasal 21 (9) 11 (7) 9 (13)   12 (8) 9 (10)  
Cell differentiation – no. (%)*6     0.023*4    0.94*4
Well differentiated 69 (31) 39 (25) 29 (43)   45 (31) 24 (29)  
Moderately differentiated 111 (49) 84 (54) 26 (39)   70 (49) 41 (50)  
Poorly differentiated 45 (20) 33 (21) 12 (18)   28 (20) 17 (21)  
Stages – no. (%)*6     0.12*4    0.97*4
I 12 (5) 11 (7) 1 (1)   8 (5) 4 (5)  
II 48 (21) 34 (21) 14 (20)   29 (20) 19 (22)  
III 48 (21) 28 (18) 20 (29)   30 (21) 18 (21)  
IV 124 (53) 87 (54) 35 (50)   79 (54) 45 (52)  
Anticancer therapy – no. (%)        
Radiotherapy ± Chemotherapy 27 (12) 22 (13) 4 (6) 0.13*4 15 (10) 12 (14) 0.41*4
CDKN2A-SCNAs – no. (%)*6     0.73*4    0.035*4
Norma 174 (77) 117 (76) 55 (80)   99 (72) 75 (86)  
Heterozygous deletion 39 (17) 29 (19) 10 (14)   29 (21) 10 (11)
Homozygous deletion 12 (5) 8 (5) 4 (6)   10 (7) 2 (2)  
p16 (+) – no. (%) 47 (20) 28 (17) 19 (27) 0.10*4 24 (16) 23 (26) 0.062*4
UGT2B17 CNVs – no. (%)*6     0.60*4    0.95*4
Homozygous deletions: 0 copy 181 (80) 124 (81) 55 (80)   111 (80) 70 (80)  
Heterozygous deletion: 1 copy 42 (19) 28 (18) 14 (20)   26 (19) 16 (18)  
Normal: 2 copies 2 (1) 2 (1) 0 (0) 0.60*4 1 (1) 1 (1) 0.95*4
  1. *1Smoking history was unavailable for two of the 234.
  2. *2Non-smokers were defined as having a <10-PYs history; smokers were defined as having a ≥10-PYs history.
  3. *3Mann-Whitney test was used to calculate the p-value.
  4. *4χ2 test was used to calculate the p-value. *5Student’s t test was used to calculate the --value.
  5. *6Because of rounding, total values are not always 100%. *7RR, 1.29; 95% CI, 1.00 to 1.65.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us